Skip to content

Censo Biotechnologies (Axol Bioscience)

Sector:
Healthcare Services
Invested in:
Calculus EISs, Calculus VCT

Axol and CENSO supply high quality adult human cells, especially live human neurons, created by stem cell technology, to many of the world’s biggest and best-known pharma companies and research institutions.

Axol Bioscience merged with Censo Biotechnologies in March 2021.

These induced pluripotent stem cells (iPSCs), which are derived from healthy adult patients of specific disease backgrounds, are used for medical research, disease modelling and drug development.

The merger of Axol and CENSO creates a global leader in the research and production of iPSC derived cell lines and custom service work. With customers in the US, Europe and Asia, the combined entity will have manufacturing sites in Cambridge and Edinburgh, increasing production capacity to ensure growing demand can continue to be met with short lead times and high quality output.

Rationale

Funds from Calculus Capital will enable growth of the combined business and acquisition of talent in order to meet customer demand.

Latest News

Calculus Capital invests in Axol Bioscience following merger with Censo Biotechnologies

Biotech sector-leaders combine tools, talent, and technologies to drive life science discovery forward Merger accompanied by £3.8million ($5.3m USD) investment across existing shareholders and new investors, which will be used to fund recruitment and growth of the business Axol Bioscience Ltd, an established provider of stem cells produced from reprogrammed human blood and tissue cells, … Continued

Other Healthcare Services Investments

eConsult

eConsult Health is the leading online consultation provider to the NHS for primary care

Learn more

Browse by sector

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information

Important Information

The investments referred to in this website are not suitable for all investors. Calculus Capital Limited is not able to give advice to prospective investors about the suitability of the investments. Prospective investors are recommended to seek specialist tax and financial advice before investing in the Calculus EIS Fund or Calculus VCT.

An investment into the Calculus EIS Fund of Calculus VCT may only be made on the basis of reading in full the information set out in the relevant Information Memorandum or prospectus.

When investing, your capital is at risk. The value of shares and income from them may go down as well as up and despite the tax relief you may not recover the amount originally invested. An investment in smaller and unquoted companies carries a higher risk than many other forms of investment. Shares in unquoted companies are not readily marketable. You should not invest in an EIS or VCT unless you can afford to lose some or all of your capital.

An EIS or VCT investment is only appropriate for investors with a medium to long term investment horizon; the timing and extent of realisation cannot be predicted and may extend beyond five years. It is not possible to allow a partial withdrawal of your investment. You may request a total withdrawal, but since many investments made will be in unquoted companies, this may not be possible. Withdrawal within three years for the EIS and five years for the VCT would lead to repayment of any tax reliefs received.

The tax benefits available depend upon your individual circumstances and these benefits may change dependent upon future legislation.

I have read and understood this important information